Li, Diyan
He, Mengnan
Tang, Qianzi
Tian, Shilin
Zhang, Jiaman
Li, Yan
Wang, Danyang
Jin, Long
Ning, Chunyou
Zhu, Wei
Hu, Silu
Long, Keren
Ma, Jideng
Liu, Jing
Zhang, Zhihua
Li, Mingzhou http://orcid.org/0000-0001-8681-7684
Funding for this research was provided by:
Beijing Advanced Discipline Fund (115200S001)
Special investigation on science and technology basic resources of the MOST, China (2019FY100102)
State Key Laboratory of Drug Research (XDA24020307)
National Natural Science Foundation of China (31671342, 31871331, 91940304, 31802044, U19A2036, 31872335, 31772576)
Beijing Natural Science Foundation (Z200021)
National Key R&D Program of China (2018YFC2000400, 2020YFA0509500)
Sichuan Science and Technology Program (2021YFYZ0009, 2021YFYZ0030)
Article History
Received: 8 September 2021
Accepted: 20 April 2022
First Online: 6 May 2022
Declarations
:
: All animal protocols were approved by the Institutional Animal Care and Use Committee of the Institute of Animal Genetics and Breeding, Sichuan Agricultural University (protocol number YCS-B20151604). Three human commercial cell lines (human embryonic skin fibroblasts ESF, human embryonic lung fibroblasts HPF and WI38) were obtained at 2015 from the Cell Resource Center, Peking Union Medical College, Beijing, China. These cells were collected for use after 4–6 passages.
: Not applicable.
: The authors declare that they have no competing interests.